Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and...

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Diffuse low-grade B-cell lymphomas represent a heterogeneous group of lymphoid malignancies.
• Accurate subclassification is crucial for predicting clinical behavior and guiding treatment strategies.
• Existing classification systems (Rappaport, Working Formulation, Kiel) show limitations in delineating distinct clinicopathologic entities.

Purpose of the Study:

• To correlate B-cell antigen expression with morphologic subtypes of diffuse low-grade B-cell lymphoma.
• To evaluate the contribution of immunophenotyping to clinically relevant subclassification.
• To identify distinct biologic entities within these lymphomas based on antigen profiles and clinical features.

Main Methods:

• Analysis of 56 cases of diffuse low-grade B-cell lymphoma using frozen tissue sections.
• Application of a large panel of monoclonal antibodies to determine B-cell immunophenotypes.
• Comparison of immunophenotypes with histologic subtypes defined by Rappaport, Working Formulation, and Kiel classifications.

Main Results:

• Antigen expression showed heterogeneity across all classifications but correlated well with four major subgroups defined by the Kiel classification.
• These subgroups (CLL, centrocytic lymphoma, CB/CC lymphoma, and MALT-type/immunocytoma/monocytoid B-cell lymphoma) exhibited distinct clinical features and survival probabilities.
• Specific antibodies (CD5, CD6, CD10, CD23, CD43, Leu-8, Ig heavy chain) were useful in differentiating these subgroups.

Conclusions:

• Immunophenotypic analysis provides a more precise subclassification of diffuse low-grade B-cell lymphomas than traditional morphologic classifications.
• The identified subgroups represent distinct biologic entities with characteristic clinical behaviors and prognoses.
• This approach enhances diagnostic accuracy and aids in predicting patient outcomes.